Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer

New England Journal of Medicine

Volumn 377, Issue 9, 2017, Pages 829-838

  Peters, Solange ^a   Camidge, D Ross ^c   Shaw, Alice T ^d   Gadgeel, Shirish ^e   Ahn, Jin S ^f   Kim, Dong Wan ^g   Ou, Sai Hong I ^h,i   Pérol, Maurice ^j   Dziadziuszko, Rafal ^k   Rosell, Rafael ^l   Zeaiter, Ali ^b   Mitry, Emmanuel ^b   Golding, Sophie ^b   Balas, Bogdana ^b   Noe, Johannes ^b   Morcos, Peter N ^m   Mok, Tony ⁿ  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF COLORADO   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g Seoul National University Hospital   (South Korea)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Transportation Research Institute   (United States)

^j CENTRE LÉON BÉRARD   (France)

^k MEDICAL UNIVERSITY OF GDANSK   (Poland)

^l CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^m Roche Innovation Center   (United States)

ⁿ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CH 5424602; CRIZOTINIB; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLURRED VISION; BRAIN SURGERY; CANCER MORTALITY; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSGEUSIA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOSURGERY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VISUAL IMPAIRMENT; VOMITING; WHOLE BRAIN RADIOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SECONDARY; YOUNG ADULT;

ADULT; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; YOUNG ADULT;

EID: 85027524894     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1704795     Document Type: Article

References (16)

1. Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
2. Rangachari D, Yamaguchi N, Vander-Laan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015;88:108-11.
3. Toyokawa G, Seto T, Takenoyama M, Ichinose Y. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev 2015;34:797-805.
4. Toyokawa G, Seto T. Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol Res Treat 2015;38:291-8.
5. Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014;351:215-21.
6. Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016;6:1118-33.
7. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015;21:2227-35.
8. Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014;12:429-39.
9. Mologni L, Ceccon M, Pirola A, et al. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget 2015; 6:5720-34.
10. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H. Anti-tumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharma-col 2014;74:1023-8.
11. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28.
12. Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a Phase II global study. J Clin Oncol 2016; 34:661-8.
13. Lu S, Mok T, Lu Y, et al. Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2016;34:Suppl:9058. abstract.
14. Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017 May 10 (Epub ahead of print).
15. Soria J-C, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389:917-29.
16. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016;17:234-42.